Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIRT 2-HNC
NCT04938609Phase 2Active, not recruiting
- Start
- Jan 2022
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC). Started Jan 2022; status: active, not recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04938609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04938609.